) --




) hit a new 52-week high Monday as it is currently trading at $45.40, above its previous 52-week high of $45.34 with 1.3 million shares traded as of 11:15 a.m. ET. Average volume has been 3.6 million shares over the past 30 days.

GlaxoSmithKline has a market cap of $113.5 billion and is part of the

health care

sector and


industry. Shares are up 14.1% year to date as of the close of trading on Friday.

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. The company has a P/E ratio of 45.3, above the average drugs industry P/E ratio of 22.4 and above the S&P 500 P/E ratio of 17.7.

  • Practice your GSK trading strategies and win cash in our stock game.

TheStreet Ratings rates GlaxoSmithKline as a


. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, solid stock price performance, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated. You can view the full

GlaxoSmithKline Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center